BPX 201

Drug Profile

BPX 201

Alternative Names: AP-1903 activated BPX 201; BPX-201; Rimiducid activated BPX 201; Second generation autologous DeCIDe vaccine (BPX-201) - Bellicum Pharmaceuticals

Latest Information Update: 22 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bellicum Pharmaceuticals
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 01 Sep 2017 Phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease) is ongoing in USA (Intradermal, Injection)
  • 01 Sep 2017 Bellicum Pharmaceuticals completes a phase I trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (Intradermal) (NCT01823978)
  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top